FDA grants traditional approval for Leqembi for the treatment of Alzheimer ' s disease
STOCKHOLM, July 7, 2023. BioArctic AB ' s partner Eisai announced today that the U.S. Food and Drug Administration, FDA, has approved the supplemental Biologics License Application, sBLA, supporting the traditional approval of LEQEMBI (lecanemab-irmb)...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Alzheimer's | Clinical Trials | Food and Drug Administration (FDA) | Grants | Pharmaceuticals